|
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 0.10% | Shs Outstand | 35.85M | Perf Week | -7.20% |
| Market Cap | 524.21M | Forward P/E | - | EPS next Y | -1.58 | Insider Trans | 0.00% | Shs Float | 31.36M | Perf Month | -21.02% |
| Income | - | PEG | - | EPS next Q | -0.36 | Inst Own | 82.60% | Short Float | 3.85% | Perf Quarter | - |
| Sales | 9.44M | P/S | 55.52 | EPS this Y | -163.20% | Inst Trans | - | Short Ratio | 4.99 | Perf Half Y | - |
| Book/sh | 6.35 | P/B | 2.21 | EPS next Y | 45.10% | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | 7.53 | P/C | 1.87 | EPS next 5Y | - | ROE | - | 52W Range | 13.00 - 37.61 | Perf YTD | -56.09% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | 44.00% | 52W High | -62.64% | Beta | - |
| Dividend % | - | Quick Ratio | 9.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 8.08% | ATR | 1.39 |
| Employees | 33 | Current Ratio | 9.40 | Sales Q/Q | -67.90% | Oper. Margin | - | RSI (14) | 30.52 | Volatility | 7.84% 7.78% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 19.90% | Profit Margin | - | Rel Volume | 0.38 | Prev Close | 13.72 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 242.14K | Price | 14.05 |
| Recom | 1.50 | SMA20 | -15.82% | SMA50 | -25.64% | SMA200 | -29.16% | Volume | 92,525 | Change | 2.41% |
 | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
| Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. | ||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite